Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Canada LP

Division of Bausch Health Companies Inc.
www.valeantcanada.com

Latest From Valeant Canada LP

Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.

Deals M & A

Asia Deal Watch: Astellas Looks To Vector Cell Tech From Japan’s RiKen In Oncology

RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.

Deals Business Strategies

Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?

Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.

Market Access Pricing Strategies

Deal Watch: Cigna Acquisition Of Express Scripts OKed By US Justice Dept.

It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Alias(es)
  • Valeant Canada Ltd.
  • ICN Canada Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Bausch Health Companies Inc.
  • Senior Management
  • Thierry Lavoie, Bus. Dev. Mgr.
  • Contact Info
  • Valeant Canada LP
    Phone: (514) 744-6792
    2150 boul. St-Elzéar Ouest
    Laval, H7L 4A8
    Canada
UsernamePublicRestriction

Register